Academic Journal
Heterogeneous Causes of Acute Respiratory Distress Syndrome Correlate With Distinct Peripheral Polyunsaturated Fatty Acid Metabolites.
| Τίτλος: | Heterogeneous Causes of Acute Respiratory Distress Syndrome Correlate With Distinct Peripheral Polyunsaturated Fatty Acid Metabolites. |
|---|---|
| Συγγραφείς: | Leuenberger LA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Bednash JS; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Schott E; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Mikacenic C; Benaroya Institute, Seattle, Washington, USA., Morrell ED; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA., Richardson C; Center for Biostatistics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Fussner LA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Horowitz JC; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Mallampalli RK; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA., Shaikh SR; Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Tighe RM; Department of Medicine, Duke University, Durham, North Carolina, USA., Gowdy KM; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and The Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA. |
| Πηγή: | FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2026 May 31; Vol. 40 (10), pp. e71850. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2020- : [Bethesda, Md.] : Hoboken, NJ : Federation of American Societies for Experimental Biology ; Wiley Original Publication: [Bethesda, Md.] : The Federation, [c1987- |
| Ιατρικοί όροι (MeSH): | Respiratory Distress Syndrome*/metabolism , Respiratory Distress Syndrome*/etiology , Respiratory Distress Syndrome*/blood , Fatty Acids, Unsaturated*/metabolism , Fatty Acids, Unsaturated*/blood , Fatty Acids, Omega-3*/metabolism , Fatty Acids, Omega-3*/blood, Oxylipins/blood ; Oxylipins/metabolism ; Interleukin-6/blood ; Fatty Acids, Omega-6/blood ; Fatty Acids, Omega-6/metabolism ; Interleukin-8/blood ; Inflammation/metabolism ; Cytokines/blood ; Humans ; Female ; Male ; Middle Aged ; Aged ; Adult |
| Περίληψη: | Acute Respiratory Distress Syndrome (ARDS), a heterogeneous syndrome of hypoxic respiratory failure secondary to dysregulated pulmonary inflammation, is caused by diverse insults. This heterogeneity presents challenges for mechanistic and therapeutic research, as evidenced by conflicting results from trials of n-3 polyunsaturated fatty acid (PUFA) supplementation for ARDS. PUFAs and downstream oxylipins are important to pulmonary inflammation but are not well defined in ARDS. We hypothesized that differences in fatty acid metabolism, as measured by levels of n-3 and n-6 PUFAs and oxylipins, are associated with differences in ARDS outcomes, inflammation, and causes. To test this, PUFAs/oxylipins were measured by LC MS/MS in plasma samples from 90 patients with ARDS. Pro-inflammatory cytokines and chemokines IL-6 and IL-8 were measured by ELISA. Multivariable linear regressions modeled the relationship between PUFAs/oxylipins, inflammation, and ARDS mortality, severity, and cause. Multiple n-3 and n-6 PUFA-derived oxylipins were decreased in severe ARDS. We did not detect differences in PUFAs/oxylipins by mortality. PUFAs/oxylipins varied by cause of ARDS, especially between patients with sepsis and those with trauma. Furthermore, specific oxylipins were associated with IL-6 and IL-8. As we observed that oxylipins varied by disease severity and underlying cause, these metabolites may function as biomarkers and suggest dysregulated mechanisms of lung repair. Furthermore, while oxylipins are derived from PUFAs, differences in PUFAs did not directly correlate with changes in oxylipins, suggesting altered lipid metabolism as a mechanism. Further consideration of differences in lipid metabolism in ARDS could identify subgroups with differential responses to n-3 PUFA supplementation or other therapies. (© 2026 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.) |
| Σχόλια: | Update of: bioRxiv. 2026 Jan 10:2026.01.09.698377. doi: 10.64898/2026.01.09.698377.. (PMID: 41542631) |
| References: | Eur J Pharmacol. 2016 Aug 15;785:144-155. (PMID: 26546247) Nutr Res. 2025 Oct;142:63-75. (PMID: 41016118) Lancet Respir Med. 2020 Mar;8(3):247-257. (PMID: 31948926) Nutrition. 2019 May;61:84-92. (PMID: 30703574) JAMA. 2012 Jun 20;307(23):2526-33. (PMID: 22797452) J Immunol. 2021 Jan 15;206(2):329-334. (PMID: 33277388) Nat Rev Immunol. 2008 May;8(5):349-61. (PMID: 18437155) J Immunol. 2010 Jan 15;184(2):836-43. (PMID: 20007539) Nutr J. 2018 May 31;17(1):57. (PMID: 29859104) Microorganisms. 2025 Sep 19;13(9):. (PMID: 41011521) J Lipid Res. 2025 Oct;66(10):100897. (PMID: 40930383) Crit Care Med. 2023 Jan 1;51(1):e13-e18. (PMID: 36519995) J Clin Med. 2022 Dec 30;12(1):. (PMID: 36615103) Prostaglandins Other Lipid Mediat. 2012 Dec;99(3-4):57-67. (PMID: 23064030) JAMA. 2016 Feb 23;315(8):801-10. (PMID: 26903338) Elife. 2024 Apr 05;12:. (PMID: 38578269) N Engl J Med. 2017 Nov 9;377(19):1904-1905. (PMID: 29117492) Nat Commun. 2025 Aug 2;16(1):7088. (PMID: 40751044) N Engl J Med. 2014 Jun 5;370(23):2191-200. (PMID: 24835849) Respir Care. 2020 Jan;65(1):99-110. (PMID: 31506339) Am J Respir Cell Mol Biol. 2025 Nov;73(5):741-754. (PMID: 40208640) Clin Transl Med. 2023 Nov;13(11):e1440. (PMID: 37948331) Shock. 2022 Apr 1;57(4):565-575. (PMID: 35271545) Am J Respir Crit Care Med. 2024 Jan 1;209(1):37-47. (PMID: 37487152) Br J Clin Pharmacol. 2016 May;81(5):807-18. (PMID: 26624855) JAMA. 2011 Oct 12;306(14):1574-81. (PMID: 21976613) Front Immunol. 2020 Dec 09;11:580598. (PMID: 33362766) Clin Transl Sci. 2021 Mar;14(2):683-691. (PMID: 33202089) Nutr Bull. 2025 Mar;50(1):12-29. (PMID: 39659132) Front Med (Lausanne). 2025 Sep 23;12:1569013. (PMID: 41064518) Lancet Respir Med. 2014 Aug;2(8):611-20. (PMID: 24853585) BMC Bioinformatics. 2017 Feb 20;18(1):114. (PMID: 28219348) PPAR Res. 2019 Aug 1;2019:7242030. (PMID: 31467514) Int J Mol Sci. 2021 Jul 17;22(14):. (PMID: 34299266) J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660) Am J Clin Nutr. 2022 Mar 4;115(3):886-896. (PMID: 34964829) Essays Biochem. 2020 Sep 23;64(3):423-441. (PMID: 32808658) Crit Care Med. 2011 Jul;39(7):1655-62. (PMID: 21423000) Clin Chim Acta. 2000 Aug;298(1-2):111-20. (PMID: 10876008) J Lipid Res. 2012 Aug;53(8):1662-9. (PMID: 22628615) Sci Rep. 2020 Jan 15;10(1):333. (PMID: 31941991) N Engl J Med. 2014 Oct 30;371(18):1695-703. (PMID: 25268516) Curr Nutr Rep. 2024 Sep;13(3):527-551. (PMID: 39031306) FASEB J. 2014 Nov;28(11):4835-46. (PMID: 25059230) FASEB J. 2021 Jun;35(6):e21666. (PMID: 34033145) |
| Grant Information: | R01-HL081784 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); R01-HL097376 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); R01 HL171164 United States HL NHLBI NIH HHS; 2024 Young Investigator Grant CHEST Foundation (CHEST Philanthropy); R01-ES034350 HHS|National Institutes of Health (NIH); L70 HL175819 United States HL NHLBI NIH HHS; P30-DK056350 HHS|National Institutes of Health (NIH); S10OD032292 HHS|National Institutes of Health (NIH); S10RR027926 HHS|National Institutes of Health (NIH); R01-HL096376 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); R01-ES031378 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); K23-HL168328 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); T32-HL166132 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); RO1-HL171164 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); Research Grant in Critical Care CHEST Foundation (CHEST Philanthropy); R01-HL169265 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); UM1TR004548 HHS|NIH|National Center for Advancing Translational Sciences (NCATS); L30 HL175819 United States HL NHLBI NIH HHS; K08-HL169725 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI); T32 HL166132 United States HL NHLBI NIH HHS; R01-HL149676 HHS|NIH|National Heart, Lung, and Blood Institute (NHLBI) |
| Contributed Indexing: | Keywords: acute lung injury; acute respiratory distress syndrome; inflammation; lipidomics; lipids; lipids/oxidation; omega‐3 fatty acids; oxylipins; pulmonary inflammation |
| Substance Nomenclature: | 0 (Fatty Acids, Unsaturated) 0 (Oxylipins) 0 (Interleukin-6) 0 (Fatty Acids, Omega-6) 0 (Interleukin-8) 0 (Fatty Acids, Omega-3) 0 (Cytokines) |
| Entry Date(s): | Date Created: 20260513 Date Completed: 20260716 Latest Revision: 20260916 |
| Update Code: | 20260916 |
| PubMed Central ID: | PMC13170735 |
| DOI: | 10.1096/fj.202504787RR |
| PMID: | 42126874 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1530-6860 |
|---|---|
| DOI: | 10.1096/fj.202504787RR |